Is pretransplant antiarrhythmic drug therapy a risk factor?
Konertz
W
W
Department of Cardiothoracic Surgery, Westphalian Wilhelm's University Muenster, Germany.
Weyand
M
M
Deiwick
M
M
Scheld
H H
HH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000008:administration & dosage / Q000009:adverse effects; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001073:Aprindine / Q000008:administration & dosage / Q000009:adverse effects; D002423:Cause of Death; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000401:mortality*; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011183:Postoperative Complications / Q000401:mortality*; D011292:Premedication; D011405:Propafenone / Q000008:administration & dosage / Q000009:adverse effects; D011802:Quinidine / Q000008:administration & dosage / Q000009:adverse effects; D013015:Sotalol / Q000008:administration & dosage / Q000009:adverse effects; D015996:Survival Rate; D016042:Transplantation, Heterotopic / Q000401:mortality
D000889:Anti-Arrhythmia Agents; D008801:Mexiletine; D001073:Aprindine; D011405:Propafenone; D013015:Sotalol; D011802:Quinidine; D000638:Amiodarone